{"prompt": "['11 July 2019', 'ARGX-113-1704', 'ARGX-113', 'Protocol Version 3.0, Final', 'Patients who discontinue early from trial ARGX-113-1704, will not be offered the option to', 'roll over in the follow-on trial.', 'Patients who discontinue early from randomized treatment for rescue or pregnancy reasons or', 'for an SAE that is likely to result in a life-threatening situation or pose a serious safety risk', 'will also not be offered the option to roll over to the follow-on trial. Patients who discontinue', 'early from randomized treatment for other reasons and patients who have a temporary', 'interruption from randomized treatment may be offered the option to roll over to the follow-', 'on trial.', '4.6.', 'Protocol Deviations', 'The Investigator should not implement any deviation from, or changes of the protocol', 'without agreement by the Sponsor and prior review and documented approval of an', 'amendment from the Institutional Review Board/Independent Ethics Committee (IRB/IEC)', 'and Regulatory Authority as per local regulation, except where necessary to eliminate an', 'immediate hazard to trial patients, or when the change involves only logistical or', 'administrative aspects of the trial (e.g., change of telephone numbers, ). The Investigator', '(or delegate) should document and explain any deviation from the approved protocol.', 'Planned protocol exemptions or waivers will not be approved by the Sponsor.', '4.7.', 'Screen Failures, Rescreening, and Retesting', 'Evaluations at Screening and confirmation at Visit 1 will be used to determine the eligibility', 'of each patient for randomization at SEB (Visit 1). Patients who fail to meet the eligibility', 'criteria will be considered screen failures.', 'Patients may be rescreened (i.e., redoing the full assessments as per general SoA, Table 1) or', \"retested once (i.e., redoing 1 assessment) after Sponsor's written approval.\", 'Examples of conditions under which rescreening may be considered include the following:', 'Patients who required treatment for an acute illness (e.g., a urinary tract infection) or', 'have a chronic medical problem (e.g., uncontrolled hypertension) may be rescreened', 'once the illness resolved or the medical problem stabilized.', 'Examples of conditions under which retesting may be considered include the following:', 'Patients who have clinical laboratory tests value meeting one or more exclusion criteria', 'which are not in line with the medical history and clinical evaluation of the patient, may', 'be retested to confirm the value of the tests, if still allowed within the Screening period.', 'If not feasible, the patient should be rescreened.', 'argenx BVBA', 'Confidential', 'Page 61 of 110']['11 July 2019', 'ARGX-113-1704', 'ARGX-113', 'Protocol Version 3.0, Final', '4.8.', 'Early Termination of Trial or Site', 'The trial may be terminated at any time by the Sponsor for safety concerns due to serious', 'adverse events (SAEs), inability to achieve the recruitment target within reasonable time or if', \"in the Sponsor's judgment, there are no further benefits to be expected from the trial. In such\", 'a case, the Sponsor or delegate will inform the trial Investigators, institutions, and all', 'regulatory authorities.', 'The trial can also be terminated by the Regulatory Authority for any reason or if', 'recommended by the DSMB, or at a site level by the IRB/IEC. The Sponsor may close', 'individual trial sites prematurely for reasons such as poor protocol compliance or', 'unsatisfactory recruitment of patients.', '4.9.', 'End of Trial definition', 'End of trial is defined as last patient last visit.', '5.', 'TRIAL PROCEDURES', 'Every effort should be made to ensure that the protocol-required tests and procedures are', 'completed as described. When a protocol-required procedure cannot be performed, the', 'Investigator will document the reason and any corrective and preventive actions that he/she', 'has taken to ensure that the normal processes are adhered to in source documents. The trial', 'team should be informed of these incidents in a timely manner.', 'Patients should be seen for all visits on the designated days or as closely as possible to the', 'original planned visit schedule. There is a permissible window of 1 day for Treatment Cycle', 'visits (Visit 1 to Visit 9) and of 2 days for ITC visits. Every effort should be made to', 'schedule every visit on the exact day (which is relative to the Baseline visit [SEB or TCnB])', 'within the window as described in the general SoA (Table 1).', 'Each Treatment Cycle consists of 9 weekly visits over a period of 8 weeks, consisting of a', 'Treatment period of 3 weeks (4 weekly infusions) and a FU period of 5 weeks.', 'The SEB and TC[1]B will both be set at randomization (Visit 1), whilst the Baseline of each', 'subsequent Treatment Cycle (TCnB) will be set at Visit 1 of each corresponding Treatment', 'Cycle.', 'At all visits, the efficacy and quality of life assessments should be performed first, prior to', 'any other trial-specific procedure with the only exception of obtaining informed consent at', 'Screening and the weight assessment (if applicable). The MG-ADL scale needs to be', 'performed prior to all other efficacy or quality of life assessments (QMG, MGC, EuroQoL', '5 Dimensions 5 Levels [EQ-5D-5L] and MG-QoL15r). Acetylcholinesterase inhibitors must', 'be halted for at least 12 hours before the QMG assessment.', 'argenx BVBA', 'Confidential', 'Page 62 of 110']\n\n###\n\n", "completion": "END"}